Moderna: Patent ruling won't affect Covid-19 vaccine development

Moderna: Patent ruling won't affect Covid-19 vaccine development

PanARMENIAN.Net - Moderna Inc said on Friday, July 25 its formula used in developing a Covid-19 vaccine was not covered under patents owned by Arbutus Biopharma, Reuters reports.

Moderna Therapeutics is a Cambridge, Mass.-based biotech company co-founded by Armenian entrepreneur Noubar Afeyan.

An administrative court run by the U.S. Patent and Trademark Office on Thursday rejected Moderna’s arguments to invalidate a U.S. patent owned by Arbutus, sparking worries over its efforts to develop next-generation vaccines, including a coronavirus vaccine.

Moderna said the court’s ruling relates to actions it took in response to “longstanding aggressive posture” taken by Arbutus against developers of nucleic acid-based therapeutics and began well before the development of mRNA-1273, its Covid-19 vaccine candidate.

Moderna shares were up slightly in extended trading, while Arbutus shares closed down 20% on Friday.

 Top stories
Authorities said a total of 192 Azerbaijani troops were killed and 511 were wounded during Azerbaijan’s offensive.
In 2023, the Azerbaijani government will increase the country’s defense budget by more than 1.1 billion manats ($650 million).
The bill, published on Monday, is designed to "eliminate the shortcomings of an unreasonably broad interpretation of the key concept of "compatriot".
The earthquake caused a temporary blackout, damaged many buildings and closed a number of rural roads.
Partner news
---